Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13105319 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL1965094 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL5793544 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL2231718 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL25289434 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL2220171 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL25243275 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL10950109 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL25289433 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B | |
| SCHEMBL2311830 | 1.00 | USP2 (0.50) | USP2HTTLPAR5SPHK1PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | UNIV CALIFORNIA (US) | 2025-01-09 | — | — | US | disclosed |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024159117-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| WO-2023146974-A2 | ANTIVIRAL PRODRUGS, INTERMEDIATE- AND LONG-ACTING FORMULATIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4185300-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | The Regents of the University of California (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022020793-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-27 | — | — | WO | disclosed |
| CN-101909581-B | Sterol-modified amphiphilic lipids | UNIV CALIFORNIA | 2012-11-14 | — | — | CN | disclosed |
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-07-21 | — | — | US | disclosed |
| CN-101909581-A | Sterol-modified amphiphilic lipids | UNIV CALIFORNIA | 2010-12-08 | — | — | CN | disclosed |
| EP-2219587-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | The Regents of the University of California (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009064696-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177156-A1 | Sterol-Modified Amphiphilic Lipids | SREBF1, SREBF2, SGMS1 | USP2 2160/4885HTT 2662/4885LPAR5 1337/4885 |
| US-12594292-B2 | Antiviral prodrugs, intermediate-and long-acting formulations and methods | ACE2, SARS1, FURIN | USP2 1686/4885HTT 2014/4885LPAR5 783/4885 |
| US-12173029-B2 | Antiviral prodrugs, pharmaceutical formulations, and methods | MTAP, SARS1, RNGTT | USP2 2515/4885HTT 1997/4885LPAR5 2020/4885 |
| US-20250177428-A1 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | SARS1, ACE2, FURIN | USP2 1637/4885HTT 2016/4885LPAR5 509/4885 |
| US-20230287029-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | USP2 2515/4885HTT 1997/4885LPAR5 2020/4885 |
| US-20250011358-A1 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | MTAP, SARS1, RNGTT | USP2 2515/4885HTT 1997/4885LPAR5 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.